19156-54-8

Usage

Uses

Used in Organic Synthesis:
4,5,6,7-Tetrahydro-benzo[b]thiophene-3-carboxylic acid is used as a key intermediate in organic synthesis for the development of novel compounds with specific properties. Its unique structure allows for the creation of new chemical entities that can be further modified or functionalized to achieve desired characteristics.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid is used as a building block for the synthesis of potential drug candidates. Its heterocyclic nature and functional groups may contribute to the development of new therapeutic agents with improved pharmacological profiles, such as enhanced bioavailability, selectivity, and potency.
Used in Agrochemicals:
4,5,6,7-Tetrahydro-benzo[b]thiophene-3-carboxylic acid may also find applications in the agrochemical sector, where it can be utilized as a precursor for the synthesis of new pesticides or other agrochemical products. Its unique structure could potentially lead to the discovery of novel compounds with improved efficacy and selectivity in controlling pests and diseases in agriculture.
Further research and experimentation are necessary to fully explore and understand the potential of 4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid in these industries and to optimize its use in various applications.

InChI:InChI=1/C9H10O2S/c10-9(11)7-5-12-8-4-2-1-3-6(7)8/h5H,1-4H2,(H,10,11)

Upstream product

• 14559-12-7 ethyl 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 
• 4506-71-2 ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 

Downstream Products

• 913526-84-8 2-(4,5,6,7-tetrahydrobenzo[b]thiophene-3-yl)ethanamine 
• 314251-04-2 N-[5-(4-fluorobenzyl)-1,3-thiazol-2-yl]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide 
• 398137-02-5 N-[3-cyano-4-(4-hydroxypiperidin-1-yl)phenyl]-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide 

Relevant academic research and scientific papers

Ethyl 2-Aminothiophene-3-Carboxylates in the Synthesis of Isomeric Thienopyridines

A convenient method for the synthesis of thieno[3,2-c]pyridinones was developed. A number of thiophene derivatives was prepared, and the possibility of using thiophene desamino derivatives for the design of potentially biologically active molecules was demonstrated.

Fused bicyclic amide compounds and medicinal use thereof

The present invention provides a compound represented by the formula (I) wherein ring A is benzene, cyclohexane, pyridine, piperidine or a derivative thereof, imidazole or a derivative thereof and the like, ring B is benzene, cyclohexane, pyrrole or a derivative thereof, furan, thiophene and the like, R1, R2 and R3 are each hydrogen, alkyl, halogen, hydroxyl group, alkoxy and the like, W is hydrogen, alkyl or hydroxycarbonylalkyl, X is halogen, cyano, nitro and the like, X′ is hydrogen, halogen and the like, and Y is alkyl, hydroxyalkyl, hydroxycarbonylalkyl, aminoalkyl and the like, a salt thereof, and a pharmaceutical agent containing the compound. The compound of the present invention shows a superior inhibitory effect on the proliferation of activated lymphocyte and is useful as an agent for the prophylaxis or treatment of various autoimmune diseases.

Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 2. 6,6-dimethylbicyclo[3.1.1]heptane derivatives

In an earlier paper, we reported that novel prostaglandin D2 (PGD2) receptor antagonists having the bicyclo[2.2.1]heptane ring system as a prostaglandin skeleton were a potent new class of antiallergic agents and suppressed various allergic inflammatory responses such as those observed in conjunctivitis and asthma models. In the present study, we synthesized PGD2 receptor antagonists having the 6,6-dimethylbicyclo [3.1.1]heptane ring system. These derivatives have the amide moiety, in contrast to those with the bicyclo[2.2.1]heptane ring system, which have the sulfonamide group. The derivatives having the 6,6-dimethylbicyclo[3.1.1]heptane ring also exhibited strong activity in PGD2 receptor binding and cAMP formation assays. In in vivo assays such as allergic rhinitis, conjunctivitis, and asthma models, these series of derivatives showed excellent pharmacological profiles. In particular, compound 45 also effectively suppressed eosinophil infiltration in allergic rhinitis and asthma models. This compound (45, S-5751) is now being developed as a promising alternative antiallergic drug candidate.